Very Short Versus Longer Dual Antiplatelet Treatment After Coronary Interventions: A Systematic Review and Meta-analysis

ConclusionsVSDAPT significantly decreased the odds of NACEs and major bleeding by 17% and 29%, respectively, without increasing ischemic events. Thus, VSDAPT could be well tolerated and feasible after PCI with DES.Clinical Trials RegistrationOpen Science Framework (10.17605/OSF.IO/4H2JB)Graphical AbstractVery short-term DAPT significantly reduces NACE and major bleedings, without affecting mortality and ischemic events (MACE, MI, stroke, stent thrombosis and revascularization).CI confidence intervals,DAPT dual antiplatelet therapy,DES drug-eluting stents,MACE major adverse cardiovascular events,MI myocardial infarction,NACE net adverse clinical events,OR odds ratio,PCI percutaneous coronary interventions.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research